Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL5328781 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL6365 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL10336277 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL178086 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL17164701 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL4019370 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL7744729 | 0.98 | ESR1 (0.96) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL5322913 | 0.97 | ESR1 (0.94) | ESR1ESR2MEN1TP53KMT2A | |
| SCHEMBL4104443 | 0.94 | ESR1 (0.89) | ESR1ESR2MEN1TP53KMT2A | |
| Toremifene SCHEMBL21464516 | 0.93 | ESR1 (0.87) | ESR1ESR2MEN1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19618 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | RES TRIANGLE INST (US) | 2026-02-05 | — | — | US | claimed |
| US-12515027-B2 | Subcutaneous biodegradable reservoir device | RESEARCH TRIANGLE INSTITUTE (US) | 2026-01-06 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| EP-4619104-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | Novartis AG (CH) | 2025-09-24 | — | — | EP | claimed |
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |
| CN-1062901-A | The novel process of not separating geometrical isomer direct production tamoxifen citrate | SHANGHAI NO 12 PHARMACEUTICAL (CN) | 1992-07-22 | — | — | CN | claimed |
| EP-0310662-A4 | PHOTOCHARACTERIZATION AND TREATMENT OF NORMAL, ABNORMAL AND ECTOPIC ENDOMETRIUM. | VANCAILLIE THIERRY GEORGES (US) | 1989-10-04 | — | — | EP | claimed |
| US-4852579-A | Photocharacterization and treatment of normal abnormal and ectopic endometrium | KARL STORZ ENDOSCOPY GMBH AND COMPANY (DE) | 1989-08-01 | — | — | US | claimed |
| EP-0310662-A1 | PHOTOCHARACTERIZATION AND TREATMENT OF NORMAL, ABNORMAL AND ECTOPIC ENDOMETRIUM | VANCAILLIE, Thierry Georges (US) | 1989-04-12 | — | — | EP | claimed |
| WO-1988008273-A1 | PHOTOCHARACTERIZATION AND TREATMENT OF NORMAL, ABNORMAL AND ECTOPIC ENDOMETRIUM | VANCAILLIE THIERRY GEORGES (US) | 1988-11-03 | — | — | WO | claimed |
| CN-86107840-A | The improvement of synthesis of citric acid triphenylamine oxide | — | 1988-06-01 | — | — | CN | claimed |
| US-4536516-A | Alkene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-20 | — | — | US | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |